Fluoxetine and Norfluoxetine, Serum or Plasma

CPT: 80299
Updated on 11/27/2024
Print Share

Synonyms

  • Prozac®
  • Sarafem®
  • Rapiflux®
  • Prozac®
  • Prozac® Weekly
  • Sarafem®
  • Selfemra™
  • Prozac®
  • Sarafem®
  • Rapiflux®

Test Includes

This test includes fluoxetine and norfluoxetine.

Norfluoxetine

This test includes fluoxetine and norfluoxetine.


Expected Turnaround Time

3 days

3 - 6 days

3 days days


Related Documents


Specimen Requirements


Specimen

Serum or plasma


Volume

2 mL


Minimum Volume

0.5 mL


Container

Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes are not recommended
 

Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.

Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes are not recommended 

Collection

Transfer separated serum or plasma to a plastic transport tube. Trough levels are most reproducible.

Transfer separated serum or plasma to a plastic transport tube.

Transfer separated serum or plasma to a plastic transport tube. Trough levels are most reproducible.


Storage Instructions

Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.

Room temperature

Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.


Stability Requirements

TemperaturePeriod
Room temperature14 days
Refrigerated14 days
Frozen14 days

Test Details


Use

This test is used for therapeutic drug management.

The efficacy of fluoxetine in the treatment of nondelusional, moderately depressed patients is comparable to that of the tricyclic agents; its efficacy in severely depressed hospitalized patients has not been established. In limited studies, fluoxetine was useful in treating patients with atypical depression, panic disorder, and the depressed component of bipolar disorder. Fluoxetine may be indicated as initial therapy in patients with concurrent obsessive-compulsive disorder. Its efficacy in obesity and bulimia is being explored.

The selection of fluoxetine appears to be most appropriate for patients who are at special risk from sedative, hypotensive, and anticholinergic side effects caused by other antidepressants. In addition, it appears to be relatively safe for use in the elderly, although its very long elimination half-life may pose special problems for these individuals.

This test is used for therapeutic drug management.


Limitations

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Methodology

Liquid chromatography/tandem mass spectrometry (LC/MS-MS)


Reference Interval

Fluoxetine and norfluoxetine (combined total): 120–500 ng/mL

Therapeutic: fluoxetine: 91−302 ng/mL, norfluoxetine: 72−258 ng/mL. After dosing at 40 mg/day for 30 days, plasma concentration of fluoxetine in the range of 91−302 ng/mL and norfluoxetine in the range of 72−258 ng/mL were observed. In a well-designed pharmacokinetic study, with patients (N = 38) taking fluoxetine for five weeks of fixed doses between 20 mg and 80 mg per day, the majority of plasma concentrations were between 100−800 ng/mL for fluoxetine and between 100−600 ng/mL for norfluoxetine.

Fluoxetine and norfluoxetine (combined total): 120–500 ng/mL


LOINC® Map

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf